Viscoelastic Properties of Respiratory and Peripheral Muscles of COPD Patients

Comparison of Viscoelastic Properties of Respiratory Muscles and Peripheral Muscles in Chronic Obstructive Pulmonary Disease Patients With Healthy Subjects

The aim of this study was to compare the viscoelastic properties of auxiliary respiratory muscles and peripheral muscles of chronic obstructive pulmonary disease patients with healthy subjects. Myotonometry was used to evaluate the viscoelastic properties of the muscles. The viscoelastic properties of the sternoclaidus mastoid, pectoralis major, upper trapezius, deltoid, biceps brachii, rectus femoris, gastrocinemius, and tibialis anterior muscles were evaluated.

Study Overview

• Status: Completed
• Conditions: COPD; Muscle Tone Abnormalities

Detailed Description

muscle viscoelastic properties; muscle tone, stiffness and elasticity. These features may vary due to muscle overuse, lack of relaxation and recovery. The aim is to investigate these differences in COPD patients and healthy individuals.

• Study Type: Observational
• Enrollment (Actual): 60

Contacts and Locations

Study Locations

• Turkey
  • Şahinbey
    • Gaziantep, Şahinbey, Turkey, 27000
      • Gaziantep Islamic Science and Technology University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Patients with COPD who visited the chest diseases clinic and had symptoms of cough, sputum, and/or shortness of breath, along with tachypnea and/or tachycardia, that had not worsened in the past 14 days were classified as the 'Stable COPD group'.

Description

Inclusion Criteria:

• male gender,
• body mass index (BMI) between 18.5-29.9 kg/m2,
• stable COPD patients

Exclusion Criteria:

• being in the acute exacerbation period for COPD patients,
• having undergone any neurological, orthopaedic or thoracic surgery,
• presence of malignancy in any organ,
• presence of comorbidities affecting muscle atrophy (myasthenia gravis, muscular dystrophy, etc.).

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
COPD group; Patients with COPD who presented to the chest diseases polyclinic and whose symptoms of cough, sputum and/or dyspnoea accompanied by tachypnoea and/or tachycardia had not worsened in the last 14 days were defined as 'Stable COPD group' [
Control group; The control group was defined as those who did not have any systemic disease and who were normal at the end of the polyclinic examination who applied to the chest diseases polyclinic.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Respiratory functions (PEF)	Peak expiratory flow (PEF) were measured was evaluated with spirometry. It will be recorded as liters and expected percentage	1 Day
The Medical Research Council Scale	Patients simply indicate on the scale the level of activity that causes dyspnoea in them according to the activities between 0-4.	1 Day
The COPD Assessment Test	This statement describes a scale consisting of eight items, each with response values ranging from 0 to 5. The total score is calculated by summing the responses to all the items, resulting in a range from 0 to 40. A higher total score indicates a greater negative impact of the disease on the individual's quality of life and daily activities.	1 Day
Viscoelastic properties of muscles	The viscoelastic properties of the muscles (muscle tone (Hz), and elasticity (Relative), stiffness (N/m)) were measured using a hand-held myotonometer.	1 Day
Respiratory functions (FEV1)	In pulmonary function test was evaluated with spirometry. forced expiratory volume in the first second (FEV1);will be recorded as liters and expected percentage	1 Day
Respiratory functions (FVC)	In pulmonary function test was evaluated with spirometry. forced expiratory volume in the first second (FEV1);will be recorded as liters and expected percentage	1 Day
Respiratory functions (FEV1/FVC)	ratio of forced expiratory volume in the first second to vital capacity (FEV1/FVC) was evaluated with spirometry.	1 Day

Collaborators and Investigators

• Sponsor: Gaziantep Islam Science and Technology University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2024
• Primary Completion (Actual): April 1, 2024
• Study Completion (Actual): May 1, 2024

Study Registration Dates

• First Submitted: August 26, 2024
• First Submitted That Met QC Criteria: August 28, 2024
• First Posted (Actual): August 30, 2024

Study Record Updates

• Last Update Posted (Estimated): November 22, 2024
• Last Update Submitted That Met QC Criteria: November 21, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Congenital Abnormalities
• Other Study ID Numbers: 2023/391

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No